SCLX - Scilex Holding Co
8.48
0.060 0.708%
Share volume: 22,584
Last Updated: 03-06-2026
Pharmaceutical Products/Biological Products, Except Diagnostic Substances:
0.17%
PREVIOUS CLOSE
CHG
CHG%
$8.42
0.06
0.01%
View ratios
| Fiscal Date | 03-31-2024 | 06-30-2024 | 09-30-2024 | 03-31-2025 | 09-30-2025 | |
|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2024 | Q2 2024 | Q3 2024 | Q1 2025 | Q3 2025 | |
| Report Date | 05-13-2024 | 08-13-2024 | 01-17-2025 | 05-14-2025 | 11-14-2025 | |
| Total revenue | 10.884 M | 16.370 M | 14.436 M | 5.004 M | 10.560 M | |
| Cost of revenue | 3.840 M | 4.390 M | 3.768 M | 1.384 M | 3.329 M | |
| Gross profit | 7.044 M | 11.980 M | 10.668 M | 3.620 M | 7.231 M | |
| 70.07% | -10.95% | -66.07% | 99.75% | |||
| Operating expenses | 32.386 M | 26.602 M | 32.083 M | 30.516 M | 192.723 M | |
| Selling general and admin | 29.278 M | 24.598 M | 29.734 M | 28.060 M | 188.824 M | |
| Research and development | 3.108 M | 2.004 M | 2.349 M | 2.456 M | 3.899 M | |
| Total expenses | 37.253 M | 27.603 M | 30.585 M | 31.518 M | 193.743 M | |
| -25.90% | 10.80% | 3.05% | 514.71% | |||
| Operating income | -26.369 M | -15.623 M | -19.917 M | -27.898 M | -186.512 M | |
| Ebit | -26.369 M | -37.011 M | -3.812 M | -23.599 M | -255.021 M | |
| Pretax income | -24.377 M | -37.582 M | -4.388 M | -26.080 M | -257.819 M | |
| 54.17% | -88.32% | 494.35% | 888.57% | |||
| Income tax | 0.000 | 0.000 | 0.000 | 0.000 | 1.000 K | |
| Net income basic | -24.377 M | 0.000 | 0.000 | 0.000 | 0.000 | |
| 100.00% | ||||||
| Net income | -24.377 M | -37.582 M | -4.388 M | -26.080 M | -257.820 M | |
| -54.17% | 88.32% | -494.35% | -888.57% |